| |
A. Kirk Field, Ph.D.
A. Kirk Field, PhD is Chairman of the Scientific Advisory Board and a member of the Board of Directors. Dr. Field has had a distinguished career encompassing over thirty years of research and management experience with pharmaceutical and biotechnology companies. Most recently, he held the position of Vice President, Research, at Hybridon. Previously, Dr. Field held high-ranking anti-infective discovery and development positions at Merck and Bristol-Myers Squibb. He is also an Adjunct Professor at the University of Massachusetts Medical School and serves on numerous editorial boards of journals that focus on anti-infective drug discovery. Dr. Field has published extensively in anti-infective drug discovery research and is an expert on antiviral drug discovery. He holds a Ph.D. in virology/immunology/biochemistry from the University of California, Berkeley.
|
Neal C. Brown, Ph.D.
Neal C. Brown, Ph.D., is a founding scientist and consultant to Microbiotix and a member of the Scientific Advisory Board and Board of Directors. Dr. Brown is a retired Professor of Pharmacology at the University of Massachusetts Medical School and served as Chairman of the Department of Pharmacology and Molecular Toxicology. Dr. Brown is an internationally recognized leader in the field of microbial DNA replication and has been instrumental in characterizing the DNA polymerases of Gram-positive bacteria. These studies are documented in numerous manuscripts in highly respected journals. He is a co-inventor on the University of Massachusetts Medical School patent covering the polymerase III inhibitors. Dr. Brown’s laboratory continues in the characterization of the polymerase III enzymes and their inhibitors.
|
George E. Wright, Ph.D.
George E. Wright, Ph.D., is a founding scientist and consultant to Microbiotix and a member of the Scientific Advisory Board and Board of Directors. Dr. Wright is a retired professor of Pharmacology at University of Massachusetts Medical School. Dr. Wright earned his doctorate at the University of Illinois, Chicago, and pursued an academic career as Professor of Pharmacology at the University of Massachusetts Medical School until 1996 when he founded GLSynthesis, Inc. Dr. Wright is an internationally respected synthetic organic chemist and a leader in the area of designing inhibitors of bacterial polymerase III. Dr. Wright is a co-inventor of the University of Massachusetts Medical School polymerase III inhibitor patent and an author of numerous manuscripts in the field of medicinal chemistry.
|
Richard T. Ellison, III, M.D.
Richard T. Ellison, III, M.D., is Professor of Medicine, Molecular Genetics, and Microbiology at the University of Massachusetts Medical School, and Associate Director, Division of Infectious Diseases and Immunology, UMass Memorial Healthcare. Dr. Ellison earned his M.D. degree from Hahnemann Medical College and continued his distinguished career at Rhode Island Hospital, the University of Colorado School of Medicine, and the Department of Veterans Affairs Medical Center, prior to becoming Clinical Director, Division of Infectious Diseases and Immunology at the University of Massachusetts Medical Center. Dr. Ellison also presently serves as President of the Massachusetts Infectious Disease Society. His scientific and clinical interests focus on antimicrobial drug research and problems of antibiotic resistance. He also serves as Deputy Editor of the Journal Watch for Infectious Diseases.
|
Robert Moellering, M.D.
Robert Moellering, M.D., is the Shields Warren-Mallinckrodt Professor Medical Research at Harvard Medical School and Physician-in-Chief and Chairman of the Department of Medicine at Beth Israel Deaconess Medical Center. Dr. Moellering received his M.D. degree cum laude from Harvard Medical School and continued his distinguished career at Massachusetts General Hospital and Harvard Medical School. He also serves as president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center. Dr. Moellering has been actively involved in research on the mechanisms of action and mechanisms of resistance of antimicrobial agents for the past 25 years. He has defined some of the important mechanisms of interaction of antimicrobial agents, particularly against Enterococcus species, a particular investigative interest of Dr. Moellering for many years. These studies have been reported extensively in scientific journals. He is the Editor-in-Chief Emeritus of Antimicrobial Agents and Chemotherapy, Editor of Infectious Disease Clinics of North America, and Editor of the European Journal of Clinical Microbiology and Infectious Diseases.
|
Richard J. Whitley, M.D.
Richard J. Whitley, M.D., is the Loeb Eminent Scholar Chair in Pediatrics; Professor of Pediatrics, Microbiology and Medicine; Director, Division of Pediatric Infectious Diseases; Vice Chairman, Department of Pediatrics; Associate Director for Clinical Studies, Center for AIDS Research; and Faculty, Gene Therapy Center at the University of Alabama at Birmingham. Dr. Whitley earned his M.D. degree at George Washington University School of Medicine and continued his distinguished career at the University of Alabama at Birmingham. He has served on numerous study sections and boards and coordinates the NIAID antiviral clinical programs. Dr. Whitley’s scientific and clinical interests have centered on developing and evaluating antiviral therapies for the treatment of herpes virus infections, and he has been a key contributor to the clinical evaluations of some of the important antiviral drugs in use today. Most recently, Dr. Whitley has contributed to the development of gene therapy approaches to antiviral and anti-tumor therapy. Dr. Whitley has published extensively in these fields. He was honored with the Aventis Award by the American Society for Microbiology in 2000 and the International Society for Antiviral Research Award for distinguished scientific accomplishments in 1998. Dr. Whitley is presently an Editor of Antiviral Research, and is a member of the Editorial Boards of the Jounal of Infectious Diseases, Sexually Transmitted Diseases, Reviews in Medical Virology, Antimicrobial Agents and Chemotherapy, Antiviral Chemistry and Chemotherapy, Infectious Diseases Watch for Pediatricians, Seminars in Pediatric Infectious Diseases, Gene Therapy, and Medscape Infectious Disease.
|
| |
|
